Victory For BlackBerry Ltd and headache for Apple Inc (NASDAQ:AAPL) (NASDAQ:BBRY)

A United States Court ruled in favor of BlackBerry Ltd (NASDAQ:BBRY) last Saturday in its patent infringement lawsuit over Typo’s keyboards. A preliminary injunction against the sale of Typo’s Apple Inc. (NASDAQ:AAPL) iPhone keyboards was granted in March this year after BlackBerry filed a lawsuit with the United States District Court of the Northern District…

Read More

SCA Posts Steady 1Q Results and Sees Early Signs of Improving Construction Market

Swedish consumer goods company Svenska Cellulosa reported first-quarter results that largely tracked our longerterm expectations. SCA’s hygiene operations (personal care and tissue) were once again steady performers while the forest product division lagged as a result of still-weak European demand for paper and solid-wood products. After reviewing the results, we are maintaining our fair value…

Read More
Gilead Sciences GILD NASDAQ:GILD

Trading Conditions in Europe Remain Soft in TNT’s First Quarter

TNT Express’ first-quarter consolidated revenue fell 4.5% from the same period last year (down 4% excluding foreign exchange). The decline was partly the result of softer Asia Pacific business, including sluggish export activity to Europe. Price competition and a continued mix shift to loweryielding shipments in Europe also contributed. Excluding foreign exchange, revenue was down…

Read More
Gilead Sciences GILD NASDAQ:GILD

Saenz Steps Down as Santander CEO

On Monday, Banco Santander SAN announced that Alfredo Saenz has resigned as CEO ahead of a decision by Spanish regulators that would have effectively decided whether his criminal conviction should disallow him from working in banking. Until recently, Spain’s rules had prevented anyone with a criminal conviction from holding a senior position in banking. Saenz…

Read More
Gilead Sciences GILD NASDAQ:GILD

Rumors Suggest Surprising Possibility of Valeant and Actavis Combination

Media reports over the weekend suggested Valeant Pharmaceuticals VRX held merger discussions with Actavis ACT , which may now have stalled on financial considerations. Valeant had been signaling that it was seeking to pursue a large acquisition or a merger of equals, so the magnitude of the deal was not surprising, but we were a…

Read More
Home